Ignite Creation Date:
2024-05-05 @ 12:05 PM
Last Modification Date:
2024-10-26 @ 9:20 AM
Study NCT ID:
NCT00235482
Status:
COMPLETED
Last Update Posted:
2019-06-27
First Post:
2005-10-07
Brief Title:
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma PXS-X02
Sponsor:
Viralytics
Organization:
Viralytics
Study Overview
Official Title:
Intratumoural Administration of Coxsackievirus A21 for the Control of Malignant Melanoma PXS-X02
Status:
COMPLETED
Status Verified Date:
2019-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PXS-X02
Brief Summary:
The purpose of this study is to determine the safety of an injection of coxsackievirus A21 into a melanoma tumour and also to see if there is a tumour response
Detailed Description:
Coxsackievirus A21 a naturally occurring enterovirus has shown that in vivo it can infect and lyse melanoma This study is to assess safety of a single intratumoural injection of the virus into an accessible subcutaneous melanoma metastasis
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| PSX-X02 | OTHER | Viralytics Study ID | None |